Galera Therapeutics (GRTX) Competitors $0.03 +0.00 (+5.77%) As of 07/8/2025 03:53 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. CYCC, TCRT, PMCB, CLDI, ORGS, APLM, SLXN, AIM, OMGA, and CELZShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Cyclacel Pharmaceuticals (CYCC), Alaunos Therapeutics (TCRT), Nuvilex (PMCB), Calidi Biotherapeutics (CLDI), Orgenesis (ORGS), Apollomics (APLM), Silexion Therapeutics (SLXN), AIM ImmunoTech (AIM), Omega Therapeutics (OMGA), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Cyclacel Pharmaceuticals Alaunos Therapeutics Nuvilex Calidi Biotherapeutics Orgenesis Apollomics Silexion Therapeutics AIM ImmunoTech Omega Therapeutics Creative Medical Technology Galera Therapeutics (NASDAQ:GRTX) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, media sentiment, valuation, institutional ownership, dividends, analyst recommendations and profitability. Do analysts recommend GRTX or CYCC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable valuation and earnings, GRTX or CYCC? Cyclacel Pharmaceuticals has higher revenue and earnings than Galera Therapeutics. Galera Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGalera TherapeuticsN/AN/A-$59.08M-$0.35-0.08Cyclacel Pharmaceuticals$40K132.72-$11.21M-$56.00-0.06 Which has more risk & volatility, GRTX or CYCC? Galera Therapeutics has a beta of 1.89, meaning that its share price is 89% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Does the media prefer GRTX or CYCC? In the previous week, Cyclacel Pharmaceuticals had 13 more articles in the media than Galera Therapeutics. MarketBeat recorded 13 mentions for Cyclacel Pharmaceuticals and 0 mentions for Galera Therapeutics. Cyclacel Pharmaceuticals' average media sentiment score of 0.16 beat Galera Therapeutics' score of 0.00 indicating that Cyclacel Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Galera Therapeutics Neutral Cyclacel Pharmaceuticals Neutral Is GRTX or CYCC more profitable? Galera Therapeutics' return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Galera TherapeuticsN/A N/A -99.34% Cyclacel Pharmaceuticals N/A -3,648.09%-155.99% Do insiders and institutionals believe in GRTX or CYCC? 50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by insiders. Comparatively, 96.9% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryCyclacel Pharmaceuticals beats Galera Therapeutics on 7 of the 12 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.08M$778.91M$5.47B$8.95BDividend YieldN/A4.84%5.25%4.04%P/E Ratio-0.081.0926.9620.11Price / SalesN/A230.52430.20119.79Price / CashN/A23.4436.8257.86Price / Book-0.016.137.985.56Net Income-$59.08M-$27.85M$3.16B$248.40M7 Day PerformanceN/A0.67%2.39%4.67%1 Month PerformanceN/A8.48%2.18%6.64%1 Year PerformanceN/A6.72%33.82%21.31% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera Therapeutics0.2751 of 5 stars$0.03+5.8%N/A-78.9%$2.08MN/A-0.0830Gap DownCYCCCyclacel Pharmaceuticals0.7539 of 5 stars$0.32-2.5%N/A-99.1%$7.65M$40K-0.0114Stock SplitTCRTAlaunos Therapeutics0.4899 of 5 stars$4.52-6.9%N/A-20.5%$7.41M$10K-1.7840PMCBNuvilex0.8871 of 5 stars$1.08-1.4%N/A-49.5%$7.37MN/A1.454Positive NewsCLDICalidi Biotherapeutics0.4661 of 5 stars$0.23-1.7%N/A-79.3%$7.15M$50K0.0038News CoverageGap UpORGSOrgenesisN/A$1.48-1.7%N/AN/A$7.08M$662K0.00150News CoverageGap DownAPLMApollomics0.3356 of 5 stars$6.38-2.8%N/A-65.8%$7.01M$1.49M0.0045News CoveragePositive NewsGap DownSLXNSilexion TherapeuticsN/A$0.81-0.4%$5.00+519.6%N/A$6.95MN/A0.00N/AAIMAIM ImmunoTech1.6705 of 5 stars$9.09+5.1%$275.00+2,925.3%-75.3%$6.95M$146K-19.3420Gap UpOMGAOmega Therapeutics2.1196 of 5 stars$0.13-21.8%$8.50+6,700.0%-93.0%$6.92M$8.10M-0.09120Gap UpCELZCreative Medical TechnologyN/A$2.65-0.2%N/A-24.6%$6.85M$10K-0.695Positive News Related Companies and Tools Related Companies CYCC Competitors TCRT Competitors PMCB Competitors CLDI Competitors ORGS Competitors APLM Competitors SLXN Competitors AIM Competitors OMGA Competitors CELZ Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRTX Stock Alerts